This is the authors' abstract. We don't add key points for this paper.
Sirolimus is reportedly effective for kaposiform hemangioendothelioma. However, data on the efficacy of low-dose sirolimus therapy remain limited. This report presents two cases of neonatal and infantile kaposiform hemangioendothelioma associated with Kasabach-Merritt phenomenon successfully treated with low-dose sirolimus (serum level: 2-6 ng/mL) without any adverse events.
No takes yet. Share an insight, caveat, or question.
Uematsu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: